Medicenna is seeking BTD for bizaxofusp in rGBM.
Post# of 148246
(Total Views: 454)
Posted On: 06/24/2024 4:36:04 PM
Quote:
Medicenna is seeking BTD for bizaxofusp in rGBM.
Very good results, 88% increase in median overall survival, 13.5 months vs. 7.2 months for matched patients. Bizaxofusp binds to the IL-4 receptor and delivers a toxin to kill tumor cells and suppressor cells in the tumor micro-environment.
The one claim I have a problem with is this -
Quote:
IL-4 receptor (IL-4R) is overexpressed in > 70% of GBM but not in normal brain , therefore it is an important therapeutic target.
https://ir.medicenna.com/static-files/7599b9b...831d813838
IL-4 is also expressed in neurons and bizaxofusp would also bind to those. Which may explain the 15% of grade 3 or greater treatment related side effects consisting of brain edema / hydrocephalus and hemiparesis (partial paralysis). Given that it could also kill neurons I have to wonder if there is cognitive decline.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼